Ansell (ANN) H2 2026 earnings summary

Executive summary

• Achieved strong FY26 results with adjusted net sales growth of 5.7%, organic constant currency growth of 5.0%, and significant second-half momentum, especially in Cleanroom and the U.S. market.

• EBIT margin improved by 90 basis points to 15%, with both Healthcare and Industrial segments delivering margin expansion and volume growth in the second half.

• Adjusted EPS reached $1.486 (148.6 US¢), up 18.5% year-over-year, at the upper end of guidance, and full-year dividend increased by 35.7% to $0.681 (US68.1¢).

• Strong cash conversion of 113% and a robust balance sheet supported resilience during the Middle East crisis and U.S. tariff impacts.

• Strategic focus on commercial and operational excellence, targeted capital allocation, and customer centricity to drive future growth.

Financial highlights

• FY26 sales reached $2,140.2m, up 6.8% year-over-year; adjusted net sales grew 5.7% and adjusted EBIT rose 14.1% to $321.9m.

• EBIT margin rose to 15%, up 90 basis points from FY25; GPADE margin improved by 70 basis points to 35.5%.

• Adjusted EPS of $1.486 (148.6 US¢), up 18.5% year-over-year, including a $0.033 non-recurring benefit.

• Cash conversion rate of 113%, up from 91% in FY25; net debt/adjusted EBITDA reduced to 1.3x.

• Full-year dividend increased by 35.7% to $0.681 (US68.1¢), with a payout ratio of 45%.

Outlook and guidance

• FY27 adjusted EPS guidance set at $1.58–$1.70 (US158¢–US170¢), assuming continued sales momentum and strategic focus on higher-value products and markets.

• Expectation of a $9 million FX benefit in FY27 and continued disciplined capital allocation.

• Capex planned at $45m–$55m, prioritizing high-growth business segments.

• Continuing $200m share buyback program, with $118m completed in FY26.

• Guidance assumes ongoing macroeconomic uncertainty and flexible pricing to offset cost volatility.